Abstract
Introduction

59
Magnetic resonance imaging (MRI) is an invaluable imaging tool that can be markedly enhanced in some 60 cases with use of gadolinium-based contrast agents (GBCAs). Nephrogenic systemic fibrosis (NSF) is a 61 devastating disease described in patients with diminished renal function, and is associated with GBCA use. As 62 a result, contrast-enhanced MRI has largely been avoided in patients with kidney disease (9, 11). Free 63 gadolinium (Gd 3+ ) is present in tissues from patients with NSF and thought to be directly responsible for 64 pathophysiology of NSF (9). Factor(s) that lead to release of Gd 3+ remain unknown although transmetallation 65 has been proposed (8, 10) . 66
Calcium and hydroxyapatite bind with high affinity to the bone-matrix peptide ASARM peptide. A detailed 67 review describes the role of ASARM peptides in bone renal diseases (13). Importantly, ASARM-peptides are 68 physiological substrates for PHEX (Zn metalloendopeptidase), potent inhibitors of mineralization and chiefly 69 responsible along with renal phosphate wasting for the bone and teeth mineralization defects in inherited 70 hypophosphatemic rickets diseases (x-linked and autosomal) (1, 2, 6, 12, (14) (15) (16) (17) (18) . In summary, proteolytic 71 cleavage releases ASARM peptides from MEPE and SIBLING proteins of the bone extracellular matrix. The 72 ASARM motif when released as a peptide (ASARM peptide; 2.3 kDa), is highly reactive, acidic, phosphorylated 73 and protease-resistant. We designed a small PHEX-related peptide (SPR4 peptide, 4.2 kDa) that binds with 74 high affinity and specificity to ASARM peptides and motifs in vivo and in vitro (13, 16, 18) . Ionized calcium 75 (Ca 2+ ) and Gd 3+ share many biophysical properties. We predicted that ASARM peptide would destabilize 76 GBCA and cause Gd 3+ release. To determine whether ASARM peptide is involved in early events in NSF we 77 conducted the following experiments using SPR4 peptide as a control. 78
Methods:
79
Animals and Diets 80
Male (C57BL/6) mice (5 week) were housed at Kansas University Medical Center (KUMC) Department of 81 Laboratory Animal Resources. The policies and procedures of the animal laboratory are in accordance with 82 those detailed in the Guide for the Care and Use of Laboratory Animals published by the US Department of 83
Health and Human Services. Male wild-type (WT) or mutant X-linked hypophosphatemic rickets mice (Hyp) 84 were used for the study (N=6) and maintained on a 1% phosphorus and 2.4IU/g Vitamin-D3 diet (Harlan 85
Teklad Rodent Diet 8604, Indianapolis, IN) (18). As reported previously Hyp mice had major increases in 86 circulating ASARM peptide compared to WT (6, 13, 17, 18) .
88
Osmotic infusion of GBCA and SPR4 89
Micro-osmotic pumps (Model 1003D; Durect Corporation) containing either: 1) vehicle (44 mM Tris pH7.4/132 90 mM NaCl/19.6 μM ZnCl 2 ; 2) gadobenate 32 nmoles/hr/kg; or 3) SPR4 peptide 32 nmoles/hr/kg were 91 subcutaneously implanted and left for 3 days (total infusion over 3 days 2.2umoles/kg and N=6 mice). Serum, 92 urine, femurs, kidney and skin were collected for analysis as described previously (16, 18) . SPR4 peptide was 93 synthesized using standard techniques by Polypeptide Laboratories (San Diego, CA) as reported previously 94 (12, 16, 18) . Peptide purity was greater than 80% via HPLC and mass spectrometry. SPR4 peptide was 95 dissolved as follows: 100 µL/1 mg of peptide of 25 mM acetic acid was first added to dissolve the peptide, then 96 900 µL of 50 mM Tris pH7.4/150 mM NaCl was added and after thorough mixing 20 µL of 1 mM ZnCl 2 . Final 97 buffer composition was 44 mM Tris pH7.4/132 mM NaCl/19.6 μM ZnCl 2 . Zn is required for the Zn-binding motif 98 of SPR4 peptide to structurally optimize SPR4 structure for binding to ASARM peptide (12, 16, 18) . 99
Serum Analysis, RNA Isolation and Real Time PCR analysis 100
Blood samples were collected in serum-separator tubes and serum prepared as described previously (12, 16, 101 18). Gene expression was performed with specific primers using RNA extracted from femurs and whole 102 kidneys (N=6 mice) as previously described (12, 16, 18) . 103
High Pressure Liquid Chromatography (HPLC) & Inductively Coupled Plasma-Mass Spec (LC-ICP-MS): 104
ASARM and SPR4 peptides were synthesized as reported previously (12, 16, 18) . A Jupiter-300TM 4μ proteo 105 90 A C18 reverse phase HPLC column (150 X 4.6) (Phenomenex) with a Bio-Rad HPLC/FPLC system 106 (BioLogic DuoFlow) was used to resolve peptides and GBCAs. Measurements of free and bound Gd 3+ were 107 undertaken using LC-ICP-MS (4, 8); results shown graphically in Figure 1A . The compounds were resolved 108 using an Agilent 7500e ICPMS detector (Collision Cell 2% He) linked to an Agilent HPLC. A Shodex-Ohpak 109 HPLC column (6 µm CB802.5 HQ 80Å 8 X 300 mm) was used at 40ºC. Microcomputed tomography (µCT) using a Scanco µCT 40 system was carried out as described previously 119 with N=6 mice (5, 16). Mice bones, kidneys and skin samples (fixed and ethanol dehydrated) were scanned 120 with a high-resolution µCT (µCT40; Scanco Medical, Southeastern, PA) as previously described (5, 16). 121
Magnetic resonance imaging (MRI): kidney. 122
A 9.4 Tesla 31cm horizontal bore Varian system was used for all MRI measurements as described previously 123 (12). A customized RF probe (two-turn solenoid coil, diameter = 7 mm) was used to increase the filling factor, 124 thereby increasing the signal-to-noise ratio. Spin-echo pulse sequence was used to acquire T 1 -weighted MR 125 images (FOV = 2 cm, resolution = 153 x 153 x 400 µm 3 , TE/TR = 4 / 140 ms). 126
Statistical analyses 127
Statistical analyses were performed using PRISM5 (GraphPad Software, La Jolla, CA) as described previously 128 (16, 18). 129
Results
130
ASARM peptide induces release of Gd
3+ from GBCA and this is prevented by SPR4 peptide 131 HPLC linked to inductively coupled plasma mass spectrometry (LC-ICP-MS) was used to measure free and 132 bound gadolinium in physiologically buffered aqueous solution containing mixtures of GBCA, ASARM peptides 133 and SPR4 peptides (4, 8) . Figure 1A shows ASARM peptide-induced release of Gd 3+ from gadodiamide in 134 vitro. Addition of excess SPR4 peptide prevented Gd 3+ release. This data confirms ASARM peptides bind 135 gadodiamide, induces de-sequestration of Gd 3+ , an effect prevented by SPR4 peptide. We then used HPLC to 136 resolve both molecules and complexes ( Figure 1B ) after mixing equimolar concentrations of gadodiamide and 137 ASARM peptide. An ASARM-gadodiamide complex peak appeared that eluted later than the free ASARM 138 peptide and gadodiamide peaks. This finding provided additional evidence that ASARM peptide binds to 139 gadodiamide. We then used NMR to study this further ( Figure 1C and D). Our previous published studies using 140
N nuclear magnetic resonance (2D-NMR) and surface plasmon resonance (SPR) showed 141 ASARM peptides bind to PHEX and SPR4 in vitro and in vivo (12, 13, 16, 18) . Figure 1C 
ASARM peptide associated NSF-like pathology is prevented by SPR4 peptide 156
We next used a murine model of X-linked hypophosphatemic rickets (HYP) that has elevated ASARM 157 peptides levels in circulation and bone (12, 16, 18) . Since ASARM peptides are small (4.2 kDa), acidic, 158 reactive, highly phosphorylated with a low pI we hypothesized the excess levels in Hyp mice should contribute 159 to reduced GBCA stability and increase the risk of developing NSF-like pathology. To test this theory we 160 infused gadobenate with and without SPR4 peptide at concentrations known to neutralize excess circulating 161 ASARM peptides (12, 13, 16, 18) . SPR4 peptide prevented gadobenate-induced hyperphosphatemia and 162 hypercalcemia (Table 1A) . The hyperphosphatemia and its prevention by SPR4 was confirmed by increased 163 renal Na-dependent phosphate co-transporter (NPT2A and NPT2C) mRNA expression (Table 1B) . SPR4 164 peptide treatment also prevented a gadobenate-induced drop in bone sclerostin expression (Table 1B) . Of 165 note, a recent study showed a link with serum phosphorus in renal patients with NSF (3). This case control 166 study shows NSF patients with chronic kidney disease have significantly lower phosphorus levels compared 167 with controls. Also, other investigators have shown serum phosphate is responsible for sensitizing rats to the 168 profibrotic effects of gadodiamide (7).This is consistent with the known phosphaturic effect of ASARM peptides 169
shown by us and others and supports the ASARM model (13). Thus, exposure to GBCA in renal patients with 170 high ASARM peptide levels (relatively hypophosphatemic) is proposed to induce release of Gd GBCA effects and SPR4 in vivo. Further studies are required to confirm a direct link with NSF pathology. 175
We then tested the effects on bone by scanning resected femurs removed from Hyp mice using µCT 176 (Figure 2A ). We found significant decreased bone-volume/tissue-volume (BV/TV) after 3 days of infusion. 177 Figure 2A illustrates these changes and the drop in volumetric mineral density in gadobenate-treated mice. We 178 conclude that acute infusion of GBCA and high ASARM peptide levels in Hyp mice induced release of Gd 3+ 179 that then displaced Ca 2+ and PO4 from bone even after 3 days. SPR4 peptide co-treatment prevented the 180 gadobenate-induced changes (Figure 2A ). SPR4 peptide likely indirectly prevented the gadobenate-mediated 181 altered mineral content by binding to ASARM peptides. Also, µCT scans of kidneys and dermal sections 182 demonstrate metastatic calcification in gadobenate treated mice ( Figure 2B & C) . The micro-calcified nodules 183
were absent in mice co-treated with SPR4 peptide. This suggests that co-treatment with SPR4 peptide 184 prevents gadobenate-induced NSF-like pathology in Hyp mice. 185
ASARM peptide destabilizes GBCA in vivo and this is blocked by SPR4 peptide 186
To determine whether ASARM peptides destabilize GBCA in vivo we carried out the following experiment 187 using Hyp mice: mice were 1) injected (intraperitoneal) with gadodiamide; or 2) pretreated with a bolus of 188 SPR4 peptide (129 nmoles) and then treated 30 min later with gadodiamide. After 2 hours mice were sacrificed 189 and kidneys removed and scanned by T 1 -weighted MRI. The high intensity MRI signal reflects intact 190 
Discussion
197
Our study provides compelling evidence that ASARM peptides bind to GBCAs, induce release of Gd 3+ and 198 Figure 3C provides a scheme that explains this model. 199 Importantly, our study has limitations since the associated in vivo biological changes we described are 200 insufficient to confirm NSF pathology and could be interesting phenomena unelated to NSF. Also, our study did 201 not investigate a representative range of GBCA's with differing thermodynamic stabilities (Ktherm). Specifically, a 3x fold molar excess of SPR4 peptide relative to ASARM peptide (2.9 molar and 0.96 molar 227 respectively). Omniscan was added at 0.49 molar, see figure for combinations. We have shown previously the 228 ratio of ASARM peptide to SPR4 peptide is optimal for binding in vitro and in vivo (12, 16, 18) . The Y-axis 229 represents the percentage ratio difference of free to bound gadolinium relative to vehicle. The total free and 230 bound gadolinium for control (vehicle and Omniscan) and experimental conditions were not significantly 231 different (17400 ppm (µg/g) SD ± 8508). For all experimental conditions including vehicle we detected a 232 significant amount of free Gd (SPR) showed ASARM peptides bind to PHEX and SPR4 in vitro and in vivo (12, 16, 18) . The ) of whole kidneys measured using µCT at 6 um resolution (N=6). Note 256 that with mice treated with the GBCA MultiHance®, an increased mineral density occurs relative to HYP 257 vehicle mice and mice co-infused with SPR4 peptide and GBCA (see also B). This indicates renal ectopic 258 deposition of mineral that is likely bone-derived (see also A). 259 Figure 3A ) the MRI 265 signal is quenched compared to WT mice (photo A; Figure 3A ) and Hyp mice treated with Gd-OMN + SPR4 266 peptide (photo C; Figure 3A ). This indicates preferential de-sequestration and release of Gd3+ ion from the 267 gadodiamide vehicle in Hyp mice due to excess ASARM peptides (photo B; Figure 3B ). This is prevented in 268
SPR4 peptide prevents this in vitro and in vivo.
Hyp mice pretreated with SPR4 peptide (compare photos B and C; Figure 3A) 
